Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.33 |
| ▸ | CA2 | P00918 | 4/20 | 0.33 |
| ▸ | CA9 | Q16790 | 3/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | CA4 | P22748 | 2/20 | 0.32 |
| ▸ | CA5A | P35218 | 2/20 | 0.32 |
| ▸ | CA7 | P43166 | 2/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.32 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.32 |
| ▸ | CA6 | P23280 | 1/20 | 0.32 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.32 |
| ▸ | MGAM | O43451 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | SI | P14410 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20217971 | 0.77 | CA1 (0.33) | CA1CA2CA9CA12CA4 | |
| SCHEMBL24565310 | 0.77 | CA1 (0.33) | CA1CA2CA9CA12CA4 | |
| SCHEMBL3872664 | 0.76 | CA2 (0.39) | CA1CA2CA9CA12CA4 | |
| SCHEMBL13298724 | 0.76 | CA1 (0.36) | CA1CA2CA9CA12CA4 | |
| SCHEMBL7155857 | 0.76 | CA2 (0.39) | CA1CA2CA9CA12CA4 | |
| SCHEMBL25381577 | 0.76 | CA1 (0.36) | CA1CA2CA9CA12CA4 | |
| SCHEMBL13318313 | 0.76 | CA1 (0.36) | CA1CA2CA9CA12CA4 | |
| SCHEMBL24087875 | 0.76 | CA2 (0.39) | CA1CA2CA9CA12CA4 | |
| SCHEMBL6274588 | 0.76 | CA1 (0.34) | CA1CA2CA9CA12CA4 | |
| SCHEMBL6932666 | 0.76 | CA1 (0.36) | CA1CA2CA9CA12CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11618731-B2 | Prodrugs of kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-04-04 | — | — | US | disclosed |
| EP-3532057-B1 | PRODRUGS OF KALLIKREIN INHIBITORS | BIOCRYST PHARM INC (US) | 2022-12-21 | — | — | EP | disclosed |
| US-20210198204-A1 | PRODRUGS OF KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2021-07-01 | — | — | US | disclosed |
| US-10759759-B2 | Prodrugs of kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2020-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198204-A1 | PRODRUGS OF KALLIKREIN INHIBITORS | KLKB1, SERPINB1, KLK1 | CA1 1489/4885CA2 1661/4885CA9 622/4885 |
| US-11618731-B2 | Prodrugs of kallikrein inhibitors | KLKB1, SERPINB1, KLK1 | CA1 1489/4885CA2 1661/4885CA9 622/4885 |
| US-10759759-B2 | Prodrugs of kallikrein inhibitors | KLKB1, SERPINB1, KLK1 | CA1 1489/4885CA2 1661/4885CA9 622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.